A compound of the general formula , for use in the prophylaxis and/or treatment of optic and/or eye diseases selected from the group consisting of (i) all forms of primary and secondary glaucoma; (ii) aquired macular disorders; (iii) optic neuropathy; (iv) optic neuritis; (v) uveitis; (vi) hereditary fundus dystrophies; (vii) retinal vascular diseases; (viii) scleritis and episcleritis; (ix) retinal detachments; (x) trauma to the eye globe; (xi) vitreous opacities; (xii) myopia and degenerative myopia; (xiii) postsurgical trauma; (xiv) dry eye disease; (xv) corneal disorders; and wherein in the compound of general formula R1 stands for a group with formula or : A represents CH2, O or S, R2 and R3 independently represent hydrogen or halogen, R4 and R6 independently repressent hydrogen or a biolabile carboxylic ester forming group; R5 is selected from the group consisting of (C1-C6)alkoxy(C1-C6)alkyl which may be substituted by a (C1-C6) alkoxy, phenyl-(C1-C6)-alkyl and phenyloxy-(C1-C6)-alkyl wherein the phenyl group may be substituted with (C1-C6)alkyl, (C1-C6)-alkoxy or halogen, and naphtyl-(C1-C6)-alkyl, R7 and R8 independently represent hydrogen or a group forming a biolabile phosphonic acid ester, and all stereoisomers, as well as pharmaceutically acceptable salts thereof. for use in the prophylaxis and/or treatment of optic and/or eye diseases selected from the group consisting of (i) all forms of primary and secondary glaucoma; (ii) aquired macular disorders; (iii) optic neuropathy; (iv) optic neuritis; (v) uveitis; (vi) hereditary fundus dystrophies; (vii) retinal vascular diseases; (viii) scleritis and episcleritis; (ix) retinal detachments; (x) trauma to the eye globe; (xi) vitreous opacities; (xii) myopia and degenerative myopia; (xiii) postsurgical trauma; (xiv) dry eye disease; (xv) corneal disorders; (i) all forms of primary and secondary glaucoma; (ii) aquired macular disorders; (iii) optic neuropathy; (iv) optic neuritis; (v) uveitis; (vi) hereditary fundus dystrophies; (vii) retinal vascular diseases; (viii) scleritis and episcleritis; (ix) retinal detachments; (x) trauma to the eye globe; (xi) vitreous opacities; (xii) myopia and degenerative myopia; (xiii) postsurgical trauma; (xiv) dry eye disease; (xv) corneal disorders; and wherein in the compound of general formula R1 stands for a group with formula or : A represents CH2, O or S, R2 and R3 independently represent hydrogen or halogen, R4 and R6 independently repressent hydrogen or a biolabile carboxylic ester forming group; R5 is selected from the group consisting of (C1-C6)alkoxy(C1-C6)alkyl which may be substituted by a (C1-C6) alkoxy, phenyl-(C1-C6)-alkyl and phenyloxy-(C1-C6)-alkyl wherein the phenyl group may be substituted with (C1-C6)alkyl, (C1-C6)-alkoxy or halogen, and naphtyl-(C1-C6)-alkyl, R7 and R8 independently represent hydrogen or a group forming a biolabile phosphonic acid ester, and all stereoisomers, as well as pharmaceutically acceptable salts thereof. R1 stands for a group with formula or : A represents CH2, O or S, R2 and R3 independently represent hydrogen or halogen, R4 and R6 independently repressent hydrogen or a biolabile carboxylic ester forming group; R5 is selected from the group consisting of (C1-C6)alkoxy(C1-C6)alkyl which may be substituted by a (C1-C6) alkoxy, phenyl-(C1-C6)-alkyl and phenyloxy-(C1-C6)-alkyl wherein the phenyl group may be substituted with (C1-C6)alkyl, (C1-C6)-alkoxy or halogen, and naphtyl-(C1-C6)-alkyl, R7 and R8 independently represent hydrogen or a group forming a biolabile phosphonic acid ester, and all stereoisomers, as well as pharmaceutically acceptable salts thereof. <EOS>